101 results
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
7 Mar 24
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
-1901 through clinical development across these three very significant indications.”
R&D Highlights and Updates
Announced positive topline efficacy
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
1 Nov 23
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
focused on our mission of making a difference in the lives of patients suffering from retinal diseases.”
R&D Highlights and Updates
Accepted to present … . This increase was primarily driven by R&D spending on the ongoing EYP-1901 clinical trials, partially offset by reduced sales and marketing expense. Non
8-K
EX-99.1
3yync
2 Aug 23
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
8-K
EX-99.1
aqsln6klbbs vmd
3 May 23
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
8-K
EX-99.1
esr1 t60q6pyl8h6f
2 Nov 22
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
7:05am
8-K
EX-99.1
3o47ybhbpdzzkpe7wb
3 Aug 22
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments
7:07am
8-K
EX-99.1
dcst8pypzzx09aia
4 May 22
EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments
7:40am